

Published by
Ministry of Health, Labour and Welfare



Translated by
Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Axicabtagene ciloleucel Idecabtagene vicleucel Tisagenlecleucel Lisocabtagene maraleucel

March 28, 2024

Non-proprietary name

Axicabtagene ciloleucel

Idecabtagene vicleucel

Tisagenlecleucel

Lisocabtagene maraleucel

Safety measure

PRECAUTIONS should be revised.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revised language is underlined.

Current	Revision
Other Precautions (N/A)	Other Precautions <u>Occurrence of lymphoid neoplasm of CAR-positive T-cell origin has been reported in patients treated with another regenerative medical product containing CAR-expressing T-cells.</u>

[Reference] Harrison SJ, et al.: Blood. 2023; 142 (Suppl 1): 6939-6940

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp